Cargando…

Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report

RATIONALE: Anti-CD19-targeted chimeric antigen receptor (CAR) T cell therapy is effective in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This therapy is associated with several side effects that can be life-threatening such as cytokine release syndrome (CRS). However, chyloth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hsin-Hui, Kuo, Cheng-Yi, Ho, Ching-Liang, Chen, Yeu-Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	4800
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578660/ https://www.ncbi.nlm.nih.gov/pubmed/37832125 http://dx.doi.org/10.1097/MD.0000000000035432

Ejemplares similares

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis
por: Cao, Genmao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report
por: Yagi, Yu, et al.
Publicado: (2021)

Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020)

Arthritis of large joints shown as a rare clinical feature of cytokine release syndrome after chimeric antigen receptor T cell therapy: A case report
por: Wang, Li-Xin, et al.
Publicado: (2018)

Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP
por: Wang, Jing, et al.
Publicado: (2016)

Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis
por: Zhang, Ya, et al.
Publicado: (2015)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report
por: Zi, Fu Ming, et al.
Publicado: (2021)

Prediction of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Using Pretherapeutic [(18)F]2-Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography/Computed Tomography
por: Song, Yoo Sung, et al.
Publicado: (2015)

Effects of microRNA-21 on apoptosis by regulating the expression of PTEN in diffuse large B-cell lymphoma
por: Song, Jia, et al.
Publicado: (2017)

Coexistence of colon adenocarcinoma, diffuse large B-cell lymphoma, and myelodysplastic syndrome: A case report
por: Wang, Wei, et al.
Publicado: (2019)

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
por: Fang, Xia, et al.
Publicado: (2017)

Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma
por: Chen, Yi, et al.
Publicado: (2019)

Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era
por: Ho, Ching-Liang, et al.
Publicado: (2015)

Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma
por: Morita, Yuka, et al.
Publicado: (2022)

Isolated skeletal muscle recurrence of an originally nodal diffuse large B cell lymphoma: A case report and review of the literature
por: Spetsieris, Nikolaos, et al.
Publicado: (2018)

Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report
por: Xu, Jingyan, et al.
Publicado: (2021)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study
por: Hsiao, Liang-Tsai, et al.
Publicado: (2015)

Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports
por: Zhu, Yang-min, et al.
Publicado: (2016)

Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report
por: Shi, Xiaofeng, et al.
Publicado: (2020)

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study
por: Schiefer, Ana-Iris, et al.
Publicado: (2015)

Fatal Necrotizing Angiotropic Epstein–Barr Virus-negative Large B-cell Lymphoma: A Case Report with Unusual Clinicopathological Features In-Between Lymphomatoid Granulomatosis and T-cell/Histiocyte-rich Large B-cell Lymphoma
por: Olivieri, Attilio, et al.
Publicado: (2014)

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report
por: Imoto, Naoto, et al.
Publicado: (2021)

Diagnostic Pitfalls of Discriminating Lymphoma-Associated Effusions
por: Chen, Hung-Jen, et al.
Publicado: (2015)

Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report
por: Saito, Sumiko, et al.
Publicado: (2021)

Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report
por: Li, Youli, et al.
Publicado: (2021)

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials
por: Huang, Zeng-Yi, et al.
Publicado: (2023)

Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports
por: Wang, Hongxia, et al.
Publicado: (2020)

The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China
por: Gu, Mianmian, et al.
Publicado: (2019)

Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis
por: Cao, Susu, et al.
Publicado: (2023)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports
por: Brunet, Vanessa, et al.
Publicado: (2017)

Intravascular large b-cell lymphoma diagnosed via transjugular liver biopsy in a patient with liver dysfunction and thrombocytopenia: A Case Report
por: Kim, Mi-Jung, et al.
Publicado: (2017)

Primary B-cell non-Hodgkin lymphoma of the parotid gland: An analysis based on the SEER database
por: Chen, Xiang-Lei, et al.
Publicado: (2023)

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma
por: Ping, Nana, et al.
Publicado: (2022)

Bilateral nephromegaly due to direct leukemic cell invasion in the initial and relapse phases of T-cell acute lymphoblastic leukaemia: A case report
por: Tamura, Yoshifuru, et al.
Publicado: (2021)

Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
por: Lu, Yanyan, et al.
Publicado: (2023)

Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Inoue, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dba4cj0htpoo8nbsl0n0ajn6r2